Separations of Fluoroquinolone Antibiotics by Reversed-Phase HPLC, using Sigma-Aldrich Supelco Discovery Columns
26 Jul 2015There are more than 100 antibiotics on the market today, and many more are in development. Resistance to antibiotics is a significant problem; an antibiotic that takes a decade to bring to market can induce resistance within months of its introduction into clinical practice. Therefore, it is critical to monitor the level of antibiotics given to humans and animals and HPLC is a powerful tool for isolation and quantification of such. Antibiotics from the fluoroquinolone subclass were studied and separated by reversed-phase HPLC on Discovery RP-AmideC16, Discovery C18, and Discovery C8 columns.
Related products
Request Quote for All Products
Discovery® BIO Wide Pore C18 HPLC Column
Sigma-Aldrich SupelcoPeptide maps generated by RP-HPLC provide valuable information about protein structure, stability, and purity. To be effective, the RP-HPLC column must be able to resolve a high percentage of the peptides in the sample. The more peptides, the better the information. Discovery BIO Wide Pore C18 gives unsurpassed RP-HPLC resolution of peptide maps from enzymatic digests. The improvements in silica and bonded-phase chemistry we have incorporated into the Discovery BIO Wide Pore line improve resolution by increasing efficiency and reducing the peak tailing. An added benefit to this is the ability to analyze peptides without TFA in the mobile phase, thereby increasing the LC-MS signal.
Discovery C18 HPLC Columns
Sigma-Aldrich SupelcoClassic reversed-phases for all general-purpose applications. Features: Excellent peak shape and efficiency compared to competitive columns Classic reversed-phase retention and selectivity Excellent, no-bleed character for LC-MS applications C18 is generally more retentive than the C8 Column Details: Chemistry: C18 Particle Size: 5 µm Pore Size: 180 Å Length: 20, 30, 50, 100, 125, 150, 250 mm ID: 2.1, 3.0, 4.0, 4.6, 10.0, 21.2 mm